Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma and tripl...Show all
Company (IPO / Went public)
Phone: 781-419-1400
400 Totten Pond Road
Suite 140
Waltham, 02451
Massachusetts, United States
| Total Funding | Date of Last Funding | |
|---|---|---|
| Syndax Pharmaceuticals | $227.2M | Mar 3, 2016 |
| Amplimmune Immunology | $20M | Oct 7, 2013 |
| OncoMed Pharmaceuticals | $376.2M | Jul 18, 2013 |
| See all 22 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer | Mar 18, 2016 | Application | |
| Methods for the treatment of lung cancer | Dec 07, 2012 | Application |
Download PDF